Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Amiselimod. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 known ✓ | P21453 | 11/20 | 1.00 |
| ▸ | S1PR3 known ✓ | Q99500 | 7/20 | 0.56 |
| ▸ | S1PR4 known ✓ | O95977 | 5/20 | 0.56 |
| ▸ | S1PR5 known ✓ | Q9H228 | 5/20 | 0.56 |
| ▸ | S1PR2 known ✓ | O95136 | 3/20 | 0.48 |
| ▸ | TNNC1 | P63316 | 6/20 | 0.56 |
| ▸ | SGPL1 | O95470 | 1/20 | 0.56 |
| ▸ | GPR183 | P32249 | 1/20 | 0.56 |
| ▸ | CERS2 | Q96G23 | 1/20 | 0.56 |
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.50 |
| ▸ | THRA | P10827 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12336974 | 1.00 | S1PR1 (1.00) | S1PR1S1PR3TNNC1S1PR4S1PR5 | |
| SCHEMBL2468253 | 1.00 | S1PR1 (1.00) | S1PR1S1PR3TNNC1S1PR4S1PR5 | |
| Amiselimod SCHEMBL29691985 | 1.00 | S1PR1 (1.00) | S1PR1S1PR3TNNC1S1PR4S1PR5 | |
| Hydrochloric Acid SCHEMBL2462139 | 0.99 | S1PR1 (0.98) | S1PR1S1PR3TNNC1S1PR4S1PR5 | |
| Amiselimod SCHEMBL30029360 | 0.99 | S1PR1 (0.98) | S1PR1S1PR3TNNC1S1PR4S1PR5 | |
| Amiselimod SCHEMBL2463915 | 0.99 | S1PR1 (0.98) | S1PR1S1PR3TNNC1S1PR4S1PR5 | |
| Hydrochloric Acid SCHEMBL2465803 | 0.99 | S1PR1 (0.98) | S1PR1S1PR3TNNC1S1PR4S1PR5 | |
| SCHEMBL12336900 | 0.95 | S1PR1 (0.91) | S1PR1S1PR3TNNC1S1PR4S1PR5 | |
| Hydrochloric Acid SCHEMBL2464567 | 0.94 | S1PR1 (0.89) | S1PR1S1PR3TNNC1S1PR4S1PR5 | |
| SCHEMBL12337616 | 0.94 | S1PR1 (0.89) | S1PR1S1PR3TNNC1S1PR4S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 480 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4479083-B1 | METHODS OF TREATMENT WITH CAR CELLS IN COMBINATION WITH S1P RECEPTOR MODULATORS | PRIOTHERA SAS (FR) | 2026-04-22 | — | — | EP | claimed |
| US-12569455-B2 | Therapeutic agent for myalgic encephalomyelitis/chronic fatigue syndrome | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2026-03-10 | — | — | US | claimed |
| EP-4701663-A1 | PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS, COMBINATIONS AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2026-03-04 | — | — | EP | claimed |
| US-12548678-B2 | Methods and systems for machine learning analysis of single nucleotide polymorphisms in lupus | AMPEL BIOSOLUTIONS, LLC (US) | 2026-02-10 | — | — | US | claimed |
| EP-4640714-A2 | METHODS FOR ASSESSING RISK OF DEVELOPING A VIRAL DISEASE USING A GENETIC TEST | PML Screening, LLC (US) | 2025-10-29 | — | — | EP | claimed |
| EP-4637819-A1 | METHODS OF TREATING INFLAMMATORY DISEASES WITH COMBINATION OF TL1A INHIBITORS AND S1PR INHIBITORS | Prometheus Biosciences, Inc. (US) | 2025-10-29 | — | — | EP | claimed |
| US-20250325501-A1 | A SPHINGOSINE-1-PHOSPHATE RECEPTOR (S1PR) MODULATOR FOR USE IN TREATING A PATIENT SUFFERING FROM ALZHEIMER'S DEMENTIA | UNIV OTTO VON GUERICKE MAGDEBURG (DE) | 2025-10-23 | — | — | US | claimed |
| EP-4587005-A1 | SIP 1 RECEPTOR MODULATORS FOR USE IN THE TREATMENT OF TYPE 1 IFN MEDIATED DISEASES | Viatris Asia Pacific Pte. Ltd. (SG) | 2025-07-23 | — | — | EP | claimed |
| WO-2025109119-A1 | METHODS OF TREATMENT WITH MULTISPECIFIC ANTIGEN-BINDING PROTEINS IN COMBINATION WITH S1P RECEPTOR MODULATORS | PRIOTHERA SAS (FR) | 2025-05-30 | — | — | WO | claimed |
| US-20250170176-A1 | METHODS OF TREATMENT WITH CAR CELLS IN COMBINATION WITH S1P RECEPTOR MODULATORS | PRIOTHERA SAS (FR) | 2025-05-29 | — | — | US | claimed |
| US-20220135666-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A S1P MODULATOR | GLAS USA LLC | 2022-05-05 | — | — | US | claimed |
| EP-3819285-A1 | 4-ALKOXY-3-(TRIFLUOROMETHYL)BENZYL ALCOHOL PRODUCTION METHOD | Mitsubishi Tanabe Pharma Corporation (JP) | 2021-05-12 | — | — | EP | claimed |
| EP-3492448-B1 | 4-ALKOXY-3-(TRIFLUOROMETHYL)BENZYL ALCOHOL PRODUCTION METHOD | MITSUBISHI TANABE PHARMA CORP (JP) | 2021-03-03 | — | — | EP | claimed |
| US-10752575-B2 | 4-alkoxy-3-(trifluoromethyl)benzyl alcohol production method | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2020-08-25 | — | — | US | claimed |
| EP-3492448-A1 | 4-ALKOXY-3-(TRIFLUOROMETHYL)BENZYL ALCOHOL PRODUCTION METHOD | Mitsubishi Tanabe Pharma Corporation (JP) | 2019-06-05 | — | — | EP | claimed |
| US-20190161432-A1 | 4-ALKOXY-3-(TRIFLUOROMETHYL)BENZYL ALCOHOL PRODUCTION METHOD | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-05-30 | — | — | US | claimed |
| US-8809304-B2 | Amine compound and use thereof for medical purposes | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-08-19 | — | — | US | claimed |
| EP-1961734-B1 | AMINE COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | MITSUBISHI TANABE PHARMA CORP (JP) | 2011-09-14 | — | — | EP | claimed |
| US-20090137530-A1 | Amine Compound and Use Thereof for Medical Purposes | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-05-28 | — | — | US | claimed |
| EP-1961734-A1 | AMINE COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-08-27 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137530-A1 | Amine Compound and Use Thereof for Medical Purposes | HRH3, HRH2, HRH4 | S1PR1 370/4885S1PR3 369/4885S1PR4 451/4885 |
| US-20190161432-A1 | 4-ALKOXY-3-(TRIFLUOROMETHYL)BENZYL ALCOHOL PRODUCTION METHOD | ADH1C, ADH5, ADH1A | S1PR1 2199/4885S1PR3 1402/4885S1PR4 977/4885 |
| US-20250170176-A1 | METHODS OF TREATMENT WITH CAR CELLS IN COMBINATION WITH S1P RECEPTOR MODULATORS | S1PR1, S1PR5, S1PR4 | S1PR1 1/4885S1PR3 5/4885S1PR4 3/4885 |
| US-10752575-B2 | 4-alkoxy-3-(trifluoromethyl)benzyl alcohol production method | ADH1C, ADH5, ADH1A | S1PR1 2199/4885S1PR3 1402/4885S1PR4 977/4885 |
| US-20220135666-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A S1P MODULATOR | S1PR2, S1PR1, S1PR4 | S1PR1 2/4885S1PR3 5/4885S1PR4 3/4885 |
| US-12548678-B2 | Methods and systems for machine learning analysis of single nucleotide polymorphisms in lupus | SSB, METTL16, TLR9 | S1PR1 1311/4885S1PR3 1995/4885S1PR4 2184/4885 |
| US-12569455-B2 | Therapeutic agent for myalgic encephalomyelitis/chronic fatigue syndrome | PMP22, LTA, CD69 | S1PR1 444/4885S1PR3 848/4885S1PR4 1119/4885 |
| US-20250325501-A1 | A SPHINGOSINE-1-PHOSPHATE RECEPTOR (S1PR) MODULATOR FOR USE IN TREATING A PATIENT SUFFERING FROM ALZHEIMER'S DEMENTIA | S1PR1, S1PR5, S1PR4 | S1PR1 1/4885S1PR3 5/4885S1PR4 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.